ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Analysis of F8 Genotypes and Pharmacodynamic and Safety Biomarkers in People with Moderate or Mild Hemophilia A Receiving Emicizumab in the HAVEN 6 Trial

1F. Hoffmann-La Roche Ltd., Basel, Basel-Stadt, Switzerland, 2Claude Bernard Lyon 1 University, Lyon, Auvergne, France, 3University of Michigan, Ann Arbor, Michigan, United States, 4Cliniques Universitaires Saint-Luc, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 5University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany, Bonn, Berlin, Germany

Abstract Number: PB0671

Meeting: ISTH 2022 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: Emicizumab, a bispecific antibody that substitutes for missing or deficient activated factor (F)VIII, demonstrated a favorable safety and efficacy profile in people with moderate/mild hemophilia A (HA) in the HAVEN 6 trial (Negrier, et al. Blood 2021).

Aims: To present: a F8 genetic analysis of people with moderate/mild HA; pharmacodynamics (PD) of emicizumab; and exploratory safety biomarkers in people receiving emicizumab, in HAVEN 6 (NCT04158648).

Methods: Informed consent and ethics committee approval were obtained. F8 coding regions and exon/intron boundaries were sequenced (Sanger sequencing) and rearrangements analyzed using inverse-shifting PCR. Variants were mapped against the EAHAD F8 database, ClinVar, and gnomAD. For PD, a chromogenic FVIII activity assay containing human factors, two thrombin generation (TG) assays (triggered by FXIa and tissue factor [TF]), and activated partial thromboplastin time (aPTT) were used. Endogenous FVIII was measured using a chromogenic FVIII activity assay containing bovine factors, and FVIII antigen concentration using ELISA. Plasma levels of the safety biomarkers fibrinogen, prothrombin fragment 1.2, and D-dimer were determined.

Results: F8 genetic analysis was conducted in 67 participants. Overall, one rearrangement and 64 unique short variants were identified: 13 benign, 42 likely pathogenic/unclassified, and nine novel. After excluding benign variants, most participants (81%) had one missense F8 variant.

PD and safety biomarkers were assessed in 72 participants throughout emicizumab exposure (median 54.3 weeks; data cut-off 30 October 2021). PD markers demonstrated emicizumab activity in addition to endogenous FVIII. Mean FVIII-like activity and TG peak height increased during loading and were maintained throughout exposure, but were below normal ranges. aPTT was normalized after first emicizumab dose. Endogenous FVIII activity, antigen levels, and safety biomarker concentrations were unaffected by emicizumab.

Conclusion(s): Identified F8 mutations were consistent with mutations in people with moderate/mild HA. Emicizumab improved coagulation parameters without showing abnormal signs of interaction with endogenous FVIII or affecting safety biomarkers.

To cite this abstract in AMA style:

Kiialainen A, Negrier C, Pipe S, Beckermann B, Catalani O, Schmitt C, Hermans C, Oldenburg J, Lehle M. Analysis of F8 Genotypes and Pharmacodynamic and Safety Biomarkers in People with Moderate or Mild Hemophilia A Receiving Emicizumab in the HAVEN 6 Trial [abstract]. https://abstracts.isth.org/abstract/analysis-of-f8-genotypes-and-pharmacodynamic-and-safety-biomarkers-in-people-with-moderate-or-mild-hemophilia-a-receiving-emicizumab-in-the-haven-6-trial/. Accessed October 1, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/analysis-of-f8-genotypes-and-pharmacodynamic-and-safety-biomarkers-in-people-with-moderate-or-mild-hemophilia-a-receiving-emicizumab-in-the-haven-6-trial/